Bon Natural Life (BON) Competitors $2.00 +0.03 (+1.52%) As of 10/3/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock BON vs. VAXX, ASLN, NMTR, PTPI, BPTSY, BPTH, HEPA, VINC, PBLA, and NCNAShould you be buying Bon Natural Life stock or one of its competitors? The main competitors of Bon Natural Life include Vaxxinity (VAXX), ASLAN Pharmaceuticals (ASLN), 9 Meters Biopharma (NMTR), Petros Pharmaceuticals (PTPI), Biophytis (BPTSY), Bio-Path (BPTH), Hepion Pharmaceuticals (HEPA), Vincerx Pharma (VINC), Panbela Therapeutics (PBLA), and NuCana (NCNA). These companies are all part of the "pharmaceutical products" industry. Bon Natural Life vs. Its Competitors Vaxxinity ASLAN Pharmaceuticals 9 Meters Biopharma Petros Pharmaceuticals Biophytis Bio-Path Hepion Pharmaceuticals Vincerx Pharma Panbela Therapeutics NuCana Vaxxinity (NASDAQ:VAXX) and Bon Natural Life (NASDAQ:BON) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations. Is VAXX or BON more profitable? Company Net Margins Return on Equity Return on Assets VaxxinityN/A N/A N/A Bon Natural Life N/A N/A N/A Which has higher valuation & earnings, VAXX or BON? Bon Natural Life has higher revenue and earnings than Vaxxinity. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVaxxinityN/AN/A-$56.93M-$0.45-0.02Bon Natural Life$21.61M0.02$400KN/AN/A Does the media favor VAXX or BON? In the previous week, Bon Natural Life had 2 more articles in the media than Vaxxinity. MarketBeat recorded 2 mentions for Bon Natural Life and 0 mentions for Vaxxinity. Bon Natural Life's average media sentiment score of 0.34 beat Vaxxinity's score of 0.00 indicating that Bon Natural Life is being referred to more favorably in the news media. Company Overall Sentiment Vaxxinity Neutral Bon Natural Life Neutral Which has more risk and volatility, VAXX or BON? Vaxxinity has a beta of 17.25, suggesting that its stock price is 1,625% more volatile than the S&P 500. Comparatively, Bon Natural Life has a beta of -0.35, suggesting that its stock price is 135% less volatile than the S&P 500. Do analysts recommend VAXX or BON? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaxxinity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Bon Natural Life 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Do insiders & institutionals believe in VAXX or BON? 82.9% of Vaxxinity shares are owned by institutional investors. Comparatively, 0.6% of Bon Natural Life shares are owned by institutional investors. 64.1% of Vaxxinity shares are owned by company insiders. Comparatively, 26.5% of Bon Natural Life shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryBon Natural Life beats Vaxxinity on 5 of the 8 factors compared between the two stocks. Get Bon Natural Life News Delivered to You Automatically Sign up to receive the latest news and ratings for BON and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BON vs. The Competition Export to ExcelMetricBon Natural LifeCONSM PD IndustryDiscretionary SectorNASDAQ ExchangeMarket Cap$334K$2.36B$8.32B$10.55BDividend YieldN/A4.41%2.99%4.70%P/E RatioN/A16.7118.6426.71Price / Sales0.024.596.30179.90Price / Cash0.1915.3916.8561.25Price / Book0.011.654.876.56Net Income$400K$106.49M$256.82M$277.70M7 Day Performance4.17%-1.13%-0.09%2.41%1 Month Performance31.58%0.10%2.15%9.30%1 Year PerformanceN/A-17.81%44.79%31.22% Bon Natural Life Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BONBon Natural Life0.5502 of 5 stars$2.00+1.5%N/AN/A$334K$21.61M0.00100Short Interest ↑VAXXVaxxinityN/A$0.01+9,900.0%N/A-50.0%$1.27MN/A-0.0290Gap UpASLNASLAN PharmaceuticalsN/A$0.60flatN/AN/A$1.23M$12M-0.0330NMTR9 Meters BiopharmaN/AN/AN/AN/A$1.04MN/A0.0020PTPIPetros Pharmaceuticals0.3249 of 5 stars$0.02-3.9%N/A-99.7%$767K$5.11M-0.0120Gap DownBPTSYBiophytisN/A$2.00flatN/AN/A$702KN/A0.0030BPTHBio-Path1.6464 of 5 stars$0.07+0.1%N/A-93.1%$634KN/A0.0010Short Interest ↓Gap UpHEPAHepion Pharmaceuticals0.1399 of 5 stars$0.06+15.5%N/A-99.8%$629KN/A-0.0120Gap UpVINCVincerx Pharma2.5696 of 5 stars$0.05+1.6%$40.00+80,221.3%-99.6%$261KN/A0.0060Short Interest ↑Gap UpPBLAPanbela Therapeutics0.115 of 5 stars$0.05flatN/A-96.9%$243KN/A0.006NCNANuCana0.6017 of 5 stars$4.01+0.8%N/A-98.8%$120KN/A-0.0130Positive News Related Companies and Tools Related Companies Vaxxinity Competitors ASLAN Pharmaceuticals Competitors 9 Meters Biopharma Competitors Petros Pharmaceuticals Competitors Biophytis Competitors Bio-Path Competitors Hepion Pharmaceuticals Competitors Vincerx Pharma Competitors Panbela Therapeutics Competitors NuCana Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BON) was last updated on 10/4/2025 by MarketBeat.com Staff From Our PartnersNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingThe warning signs that preceded the 2008 crash are reappearing: an irrational NASDAQ bubble, a record-high gol...StockEarnings | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he...Banyan Hill Publishing | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bon Natural Life Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Bon Natural Life With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
